Bio-Techne Corp (NASDAQ:TECH) Reports Mixed Q4 2025 Earnings Amid Revenue Miss and EPS Beat

Bio-Techne Corp (NASDAQ:TECH) reported its fourth-quarter fiscal 2025 earnings, delivering mixed results compared to analyst expectations. The company's performance, along with the market's reaction, provides insights into investor sentiment and future expectations.

Earnings and Revenue Performance

• Revenue: Bio-Techne posted Q4 2025 revenue of $316.96 million, falling short of the consensus estimate of $321.91 million. The miss suggests potential headwinds in demand or operational execution.
• Earnings Per Share (EPS): The company reported an EPS of $0.53, slightly above the estimated $0.5089. This beat, albeit narrow, indicates better-than-expected cost management or profitability in certain segments.

Market Reaction

The stock traded down ~2.1% in pre-market activity, reflecting investor disappointment over the revenue miss. While the EPS beat may have cushioned some downside, the market appears more focused on top-line growth concerns. Over the past month, the stock has seen modest gains (+3.7%), but the immediate post-earnings reaction suggests near-term caution.

Forward-Looking Estimates

Analysts project the following for Bio-Techne:

• Q1 2026 Revenue: $305.75 million (EPS estimate: $0.45)
• Full-Year 2026 Revenue: $1.309 billion (EPS estimate: $2.12)

The company did not provide explicit guidance in the press release, leaving investors to rely on external estimates. The lack of an outlook neither reinforces nor alleviates concerns, but the revenue miss in Q4 may weigh on sentiment until clearer growth catalysts emerge.

Key Takeaways from the Press Release

• Bio-Techne’s Board of Directors declared a quarterly dividend of $0.08 per share, maintaining its shareholder return policy.
• The company continues to focus on its Protein Sciences and Diagnostics & Genomics segments, which remain central to its long-term growth strategy.

For a deeper dive into Bio-Techne’s earnings history and future estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.